Chardan Capital Markets

Shares of Axovant Sciences Ltd (NASDAQ: AXON) plummeted more than 70 percent after the company's late-stage trial involving its therapy for the treatment of Alzheimer's failed to meet its primary objectives in a phase 3 study called MINDSET. Investors thinking Axovant's stock can't see any...

Straight Path Communications Inc (NYSE: STRP) shares have been on the high since early April after AT&T Inc. (NYSE: T) clinched a $1.6 billion all-stock buyout deal for the company, valuing it at $95.63 per share. The stock was rangebound for a long time in the run-up to the announcement. Since...

AT&T Inc. (NYSE: T) announced Monday that it had agreed to acquire Straight Path Communications Inc (NYSE: STRP) in a deal valued at $1.6 billion, including liabilities. The Straight Path acquisition highlights “the scarcity value of spectrum,” and Globalstar, Inc. (NYSE: GSAT) may...

Chardan Capital’s James McIlree expects 2017 to be a “pivotal year” for Vuzix Corporation (NASDAQ: VUZI), with “ramp in production of the M300, introduction of the M3000, the Blade 3000, and waveguide products, and delivery of customized smart glasses to Toshiba in the...

Following Vuzix Corporation (NASDAQ: VUZI) reporting Q4 revenue in line with the estimate, Chardan Capital’s James McIlree mentioned that new product launches are expected to drive the company’s growth through 2017. The analyst maintained a Buy rating on the company, with a price target...

Biogen Inc (NASDAQ: BIIB) and Ionis Pharmaceuticals Inc (NASDAQ: IONS) had announced on December 23, 2016, the U.S. FDA approval for Spinraza (nusinersen) for the treatment of spinal muscular atrophy (SMA) types 1 to 3. Safety Concerns However, with regard to the safety profile of the drug, Chardan...

After the close on Monday, Amgen, Inc. (NASDAQ: AMGN) announced that the U.S. District Court of Delaware had denied the motion by Sanofi SA (ADR) (NYSE: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) to stay the injunction pending the appeal of the ongoing PCSK9 litigation in the Court of...

Chardan Capital Markets is bullish on Teladoc Inc (NYSE: TDOC) despite the software firm guiding preliminary 2017 revenue below the Street. Teladoc, which provides telehealth services to health plans and employers, expects 2017 revenue of $182.5 million at the midpoint, which represents a 49...

After market close on January 5, it was announced that U.S. Federal District Court Judge Sue Robinson had ruled to issue a permanent injunction against Praluent, the PCSK9 mAb for hypercholesterolemia from partners Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (ADR) (NYSE: SNY) due to...

Following the impressive phase II ORION-1 results for the RNAi drug, inclisiran (a PCSK9 inhibitor for hypercholesterolemia), inclisiran's “expeditious” movement into phase III trials, the injunction granted against Praluent (another PCSK9 inhibitor) Thursday and with PCSK9...

At its R&D Day in New York City on December 16, Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) discussed its clinical pipeline of RNAi drugs, including the phase III APOLLO trial of patisiran for transthyretin familial amyloid polyneuropathy (TTR-FAP). Chardan Capital’s Madhu Kumar...